Craik Lab Overview
We explore the roles and mechanisms of enzymes, receptors, and membrane proteins in complex biological processes using a vast, cross-disciplinary toolset, and we develop technologies to facilitate these studies.
Check out some of our recent papers below:
- Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus MPro inhibitors with potent in vivo efficacy (NEW)
- Recombinant Antibodies Inhibit Enzymatic Activity of the E3 Ubiquitin Ligase CHIP via Multiple Mechanisms (NEW)
- Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C-MHC I complex Demonstrates the Antitumor Efficacy of Hapten-Based Strategies (NEW)
- Preparing for the next pandemic; New lead drugs to treat COVID-19 are beginning to emerge
- Rare antibody phage isolation and discrimination (RAPID) biopanning enables identification of high-affinity antibodies against challenging targets
- High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions
- A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy
- Inhibiting a dynamic viral protease by targeting a non-catalytic cysteine
- In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET
